Adicet Bio, Inc.
ACET- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001720580
No open-market purchases or sales by Adicet Bio, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $52.8M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +7 vs. previous quarter
- 56
- 13F valueReported value at the end of Q2 2026
- $52.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ACET, Q2 2026
No superinvestor reported holding ACET at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Adicet Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 13, 2026 (view filing)5:20 PM ET | Feb 18-20 | 54 daysLate | RA Capital Healthcare Fund LP and 3 others10% Owner | PPurchase | +223.6K | $7.17 | +$1.60M | +23.3%1.18M after | 3 lots |
| Apr 9, 2026 (view filing)5:38 PM ET | Apr 7-8 | 2 days | OrbiMed Advisors LLC and 7 others10% Owner | SSale | −104.7K | $6.45 | −$674.8K | −100.0%0 after | 4 lots |
| Oct 10, 2025 (view filing)8:06 PM ET | Oct 8 | 2 days | OrbiMed Advisors LLC and 7 others10% Owner | PPurchase | +5.00M | $1.00 | +$5.00M | New position4.49M after | 2 lots |
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Kauffman MichaelDirector | SSale | −5.90K | $1.43 | −$8.44K | −50.0%5.90K after | |
| Jan 26, 2024 (view filing)7:14 PM ET | Jan 25 | 1 day | OrbiMed Advisors LLC and 7 othersDirector, 10% Owner | PPurchase | +3.13M | $2.40 | +$7.50M | New position1.26M after | 3 lotsDuplicate filing |
| Jan 26, 2024 (view filing) | Jan 25 | 1 day | Gordon Carl LDirector, 10% Owner | PPurchase | +3.13M | $2.40 | +$7.50M | New position1.26M after | 3 lots |
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Schor ChenPresident & CEO | SSale | −5.50K | $1.42 | −$7.81K | −12.7%38.0K after | |
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Schor ChenPresident & CEO | PPurchase | +5.50K | $1.42 | +$7.81K | +3.1%182.5K after | |
| Oct 2, 2023 (view filing) | Sep 29 | 3 days | Schor ChenPresident & CEO | SSale | −5.50K | $1.36 | −$7.48K | −3.0%177.0K after | |
| Oct 2, 2023 (view filing) | Oct 2 | Same day | Schor ChenPresident & CEO | PPurchase | +5.50K | $1.33 | +$7.32K | +14.5%43.5K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Adicet Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 932,624 | $8.06M | 0.07% | −250,000−21.1% | Reduced |
| OrbiMed Advisors LLC | 844,787 | $7.30M | 0.14% | −183,157−17.8% | Reduced |
| Franklin Resources Inc | 626,571 | $5.41M | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 432,738 | $3.74M | 0.00% | +50,915+13.3% | Added |
| Vanguard Capital Management LLC | 343,228 | $2.97M | 0.00% | +6,704+2.0% | Added |
| Adage Capital Partners GP, L.L.C. | 274,375 | $2.37M | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 265,945 | $2.30M | 0.00% | +33,354+14.3% | Added |
| Stonepine Capital Management, LLC | 245,518 | $2.12M | 1.61% | +23,563+10.6% | Added |
| Alyeska Investment Group, L.P. | 203,799 | $1.76M | 0.00% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 195,514 | $1.69M | 0.01% | +195,514 | New |